On July 19, 2018, the U.S. District Court, Northern District of California, denied a permanent injunction requested by Illumina, Inc, and instead ruled that a forward looking royalty for continued non-voluntary use of the invention, a type of compulsory license,… Continue Reading
The following was sent to US DOJ today, to express KEI’s opposition to the IBM acquisition of Red Hat. 13 March 2019 Bindi R. Bhagat U.S. Department of Justice Antitrust Division Technology and Financial Services Section Dear Ms. Bhagat, Thank… Continue Reading
On March 6, 2019, 83 civil society organizations and 20 individuals asked delegates to the World Health Assembly (WHA) to support a proposed resolution on “Improving the transparency of markets for drugs, vaccines and other health-related technologies.” A copy of… Continue Reading
PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading